Document is current
Any future updates will be listed below
-
Authors
Wienert, Beeke https://orcid.org/0000-0002-9867-0795
Nguyen, David N. https://orcid.org/0000-0001-6808-2717
Guenther, Alexis https://orcid.org/0000-0002-1231-1557
Feng, Sharon J.
Locke, Melissa N. https://orcid.org/0000-0001-8162-1471
Wyman, Stacia K. https://orcid.org/0000-0002-8937-8397
Shin, Jiyung
Kazane, Katelynn R.
Gregory, Georgia L. https://orcid.org/0000-0002-4918-9444
Carter, Matthew A. M.
Wright, Francis
Conklin, Bruce R.
Marson, Alex https://orcid.org/0000-0002-2734-5776
Richardson, Chris D. https://orcid.org/0000-0003-3122-4851
Corn, Jacob E. https://orcid.org/0000-0002-7798-5309
- License Information
-
More Information
Article History
Received: 6 February 2020
Accepted: 12 March 2020
First Online: 30 April 2020
Competing interests
: A.M. and J.E.C. are cofounders of Spotlight Therapeutics. J.E.C. has received sponsored research support from AstraZeneca and Pfizer. A.M. is a co-founder of Arsenal Biosciences. A.M. serves as on the scientific advisory board of PACT Pharma, is an advisor to Trizell, and was a former advisor to Juno Therapeutics. The Marson laboratory has received sponsored research support from Juno Therapeutics, Epinomics, and Sanofi and a gift from Gilead. C.D.R. is a shareholder in Spotlight Therapeutics. All other authors declare no competing interests.
